《高盛認股證牛熊證》藥明強勢 獲資金吸納好倉 留意熱門購18006、高槓桿購16466
正股表現：受主要股東減持消息影響，藥明(2269)昨日出現沽壓，收市跌約4.5%，但今早則表現強勢反彈。早上高開約0.7%後升幅擴大，最高見134.1元。現報133.1元，升約1%。
藥明公布日前獲主要股東Biologics Holdings通知，擬以每股129元配售8,000萬股現有股份，佔公司已發行股本之1.89%，涉套現103.2億元。雖較現價折讓，但今日見股價受支持。
資金流向：觀察個股輪證資金流向，好倉獲資金趁低吸納，當中認購證於本週二及本週三共錄得約250萬元資金流入。牛證同期則共錄得約380萬元資金流入，並見流入牛證的資金分佈在130元以下的各收回區域產品。
產品選擇：投資者如看好，認購證方面的熱門選擇可留意屬市場上3個月期以上的低街貨產品中，槓桿最高的藥明購18006。高槓桿選擇可留意年期約2個月的低街貨藥明購16466。貼價選擇可留意價外幅度約5%，年期約2個月的藥明購23249。
藥明購18006，行使價150.1元，2021年12月28日到期，實際槓桿4.5倍，熱門條款、市場上3個月期以上、低街貨產品中，槓桿最高
藥明購16466，行使價160.98元，2021年09月28日到期，實際槓桿6.7倍，高槓桿、低街貨
藥明購23249，行使價139.98元，2021年09月29日到期，實際槓桿6.0倍，貼價
牛證方面，投資者可留意屬遠牛的藥明牛67993，與現價有約18元收回距離。
藥明牛67993，收回價115元，行使價113.5元，換股比率100，槓桿比率6.6倍，相近收回價遠牛中槓桿最高
註: 以上數據資料來自高盛認股證牛熊證網站https://www.gswarrants.com.hk/~
重要聲明:
以上資訊由第三方提供，AASTOCKS.com Limited對於任何包含於、經由、連結、下載或從任何與本網站有關服務所獲得之資訊、內容或廣告，不聲明或保證其內容之正確性或可靠性。對於您透過本網站上之廣告、資訊或要約而展示、購買或取得之任何產品、資訊資料，本公司亦不負品質保證之責任。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
